JP2020128426A5 - - Google Patents

Download PDF

Info

Publication number
JP2020128426A5
JP2020128426A5 JP2020093126A JP2020093126A JP2020128426A5 JP 2020128426 A5 JP2020128426 A5 JP 2020128426A5 JP 2020093126 A JP2020093126 A JP 2020093126A JP 2020093126 A JP2020093126 A JP 2020093126A JP 2020128426 A5 JP2020128426 A5 JP 2020128426A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroaryl
compound according
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020093126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020128426A (ja
JP7017801B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/051214 external-priority patent/WO2019055869A1/en
Application filed filed Critical
Publication of JP2020128426A publication Critical patent/JP2020128426A/ja
Publication of JP2020128426A5 publication Critical patent/JP2020128426A5/ja
Application granted granted Critical
Publication of JP7017801B2 publication Critical patent/JP7017801B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020093126A 2018-06-29 2020-05-28 Creb結合タンパク質(cbp)の阻害 Active JP7017801B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
US62/692,593 2018-06-29
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
WOPCT/US2018/051214 2018-09-14
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
WOPCT/US2018/051235 2018-09-14
US201962819490P 2019-03-15 2019-03-15
US62/819,490 2019-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019123100A Division JP6781806B2 (ja) 2018-06-29 2019-07-01 Creb結合タンパク質(cbp)の阻害

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020209005A Division JP2021042255A (ja) 2018-06-29 2020-12-17 Creb結合タンパク質(cbp)の阻害

Publications (3)

Publication Number Publication Date
JP2020128426A JP2020128426A (ja) 2020-08-27
JP2020128426A5 true JP2020128426A5 (cg-RX-API-DMAC7.html) 2021-02-04
JP7017801B2 JP7017801B2 (ja) 2022-02-09

Family

ID=68987627

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019123100A Active JP6781806B2 (ja) 2018-06-29 2019-07-01 Creb結合タンパク質(cbp)の阻害
JP2020093126A Active JP7017801B2 (ja) 2018-06-29 2020-05-28 Creb結合タンパク質(cbp)の阻害
JP2020209005A Withdrawn JP2021042255A (ja) 2018-06-29 2020-12-17 Creb結合タンパク質(cbp)の阻害
JP2025046918A Pending JP2025094157A (ja) 2018-06-29 2025-03-21 Creb結合タンパク質(cbp)の阻害

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019123100A Active JP6781806B2 (ja) 2018-06-29 2019-07-01 Creb結合タンパク質(cbp)の阻害

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020209005A Withdrawn JP2021042255A (ja) 2018-06-29 2020-12-17 Creb結合タンパク質(cbp)の阻害
JP2025046918A Pending JP2025094157A (ja) 2018-06-29 2025-03-21 Creb結合タンパク質(cbp)の阻害

Country Status (26)

Country Link
US (3) US10870648B2 (cg-RX-API-DMAC7.html)
EP (1) EP3998266A1 (cg-RX-API-DMAC7.html)
JP (4) JP6781806B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250067962A (cg-RX-API-DMAC7.html)
CN (2) CN112513038B (cg-RX-API-DMAC7.html)
AU (3) AU2019295790B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020026783A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105099A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124762T1 (cg-RX-API-DMAC7.html)
DK (1) DK3587418T3 (cg-RX-API-DMAC7.html)
ES (1) ES2900105T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211698T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056885T2 (cg-RX-API-DMAC7.html)
IL (3) IL321337A (cg-RX-API-DMAC7.html)
LT (1) LT3587418T (cg-RX-API-DMAC7.html)
MA (1) MA50675B1 (cg-RX-API-DMAC7.html)
MX (2) MX2023013508A (cg-RX-API-DMAC7.html)
PL (1) PL3587418T3 (cg-RX-API-DMAC7.html)
PT (1) PT3587418T (cg-RX-API-DMAC7.html)
RS (1) RS62732B1 (cg-RX-API-DMAC7.html)
SA (1) SA520420909B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012767UA (cg-RX-API-DMAC7.html)
SI (1) SI3587418T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100636T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020006483A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202100509B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013508A (es) * 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).
WO2020190792A1 (en) * 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Compositions and methods for treating androgen receptor positive forms of cancer
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
MX2022016498A (es) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras.
IL299438A (en) 2020-06-25 2023-02-01 Tolremo Therapeutics Ag A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in the treatment of EGFR-mutated NSCLC
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
AU2002218190A1 (en) 2000-11-20 2002-05-27 Merck Patent G.M.B.H Chiral photoisomerizable compounds
CA2463136A1 (en) 2001-10-17 2003-04-24 Raymond Andersen Ship 1 modulators
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (cg-RX-API-DMAC7.html) 2003-11-13 2008-10-06
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CA2652235A1 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
WO2008157680A2 (en) 2007-06-21 2008-12-24 The Wistar Institute Methods and compositions for modulating p300/cbp activity
ATE539063T1 (de) 2007-06-26 2012-01-15 Sanofi Sa Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen
WO2009001817A1 (ja) 2007-06-27 2008-12-31 Taisho Pharmaceutical Co., Ltd. 11β-HSD1阻害活性を有する化合物
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
US8592465B2 (en) 2008-06-16 2013-11-26 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
JP5657642B2 (ja) 2009-04-15 2015-01-21 ジェイダブリュ ファーマセウティカル コーポレーション リバースターン類似体の新規な化合物およびその製造方法と用途
WO2010138487A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
WO2011085039A2 (en) 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
EP2542081A4 (en) 2010-03-01 2013-07-31 Gtx Inc COMPOSITIONS FOR CANCER TREATMENT
CA2800618C (en) * 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ1δ(CK1δ)阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
US9295754B2 (en) 2011-02-24 2016-03-29 Emory University Noggin inhibitory compositions for ossification and methods related thereto
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
IN2015DN02008A (cg-RX-API-DMAC7.html) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
HRP20200854T1 (hr) 2013-06-21 2020-08-21 Zenith Epigenetics Ltd. Novi biciklički inhibitori bromodomene
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶1δ/ε抑制劑之新穎經取代之吡唑并-哌
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
LT3071203T (lt) 2013-11-18 2021-05-25 Forma Therapeutics, Inc. Tetrahidrochinolino kompozicijos kaip bet bromodomeno inhibitoriai
JP2017529358A (ja) 2014-09-19 2017-10-05 ジェネンテック, インコーポレイテッド がんの処置のためのcbp/ep300阻害剤およびbet阻害剤の使用
JP6771464B2 (ja) * 2014-11-27 2020-10-21 ジェネンテック, インコーポレイテッド Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物
EP3242878B1 (en) 2015-01-08 2020-10-14 Impetis Biosciences Ltd. Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
CN115028617A (zh) 2016-05-24 2022-09-09 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ,インク. 治療用化合物
CA3075880A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
MX2023013508A (es) * 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).

Similar Documents

Publication Publication Date Title
JP2020128426A5 (cg-RX-API-DMAC7.html)
JP2010511721A5 (cg-RX-API-DMAC7.html)
JP2020531422A5 (cg-RX-API-DMAC7.html)
JP2020531418A5 (cg-RX-API-DMAC7.html)
JP2017512789A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2019522007A5 (cg-RX-API-DMAC7.html)
JP2020529994A5 (cg-RX-API-DMAC7.html)
JP2007502295A5 (cg-RX-API-DMAC7.html)
JP2018127459A5 (cg-RX-API-DMAC7.html)
JP2006505543A5 (cg-RX-API-DMAC7.html)
JP2008510828A5 (cg-RX-API-DMAC7.html)
JP2020532547A5 (cg-RX-API-DMAC7.html)
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2018535967A5 (cg-RX-API-DMAC7.html)
JP2016537358A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2009529540A5 (cg-RX-API-DMAC7.html)
JP2020502047A5 (cg-RX-API-DMAC7.html)
JP2018531218A5 (cg-RX-API-DMAC7.html)
JP2020506951A5 (cg-RX-API-DMAC7.html)
JP2010510237A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2012508252A5 (cg-RX-API-DMAC7.html)